BeiGene, Ltd. (ONC)
NASDAQ · Healthcare · Biotechnology
BeiGene, Ltd. is a Healthcare company with a market capitalization of $39.07B and a trailing P/E ratio of 61.6.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 6, 2026 | $1.96 | $0.81 | +142.0% |
| Q4 2025 | February 26, 2026 | $0.58 | $1.60 | -63.7% |
| Q3 2025 | November 6, 2025 | $1.09 | $0.86 | +26.7% |
| Q2 2025 | August 6, 2025 | $0.84 | $0.26 | +223.1% |
| Q1 2025 | May 7, 2025 | $0.01 | $-0.74 | +101.4% |
| Q4 2024 | February 27, 2025 | $-1.43 | $-1.01 | -41.6% |
Short Interest
FINRA-reported short interest for semi-monthly settlement dates, published about nine business days after each settlement. Share counts are adjusted to the current split basis.
| Settlement | Shares Short | % of Shares Out | Days to Cover | Change |
|---|---|---|---|---|
| July 15, 2026 | 926,986 | 0.80% | 2.6 | +17.1% |
| June 30, 2026 | 791,577 | 0.68% | 2.7 | -12.3% |
| June 15, 2026 | 902,392 | 0.78% | 2.9 | -17.2% |
| May 29, 2026 | 1,089,330 | 0.94% | 4.9 | +4.1% |
| May 15, 2026 | 1,046,818 | 0.90% | 4.2 | -5.8% |
| April 30, 2026 | 1,110,932 | 0.98% | 5.9 | -3.7% |
| April 15, 2026 | 1,154,033 | 1.02% | 5.3 | -5.0% |
| March 31, 2026 | 1,214,628 | 1.07% | 5.9 | -19.5% |
Other Biotechnology Stocks
Frequently Asked Questions
What is BeiGene, Ltd.'s market cap?
As of August 13, 2026, BeiGene, Ltd. (ONC) has a market capitalization of $39.07B.
What is BeiGene, Ltd.'s P/E ratio?
BeiGene, Ltd. trades at a trailing price-to-earnings (P/E) ratio of 61.6. Its forward P/E is 51.1.
Does BeiGene, Ltd. pay a dividend?
BeiGene, Ltd. does not currently pay a dividend.
What sector is ONC in?
BeiGene, Ltd. is in the Healthcare sector, specifically the Biotechnology industry.
What is BeiGene, Ltd.'s short interest?
As of the July 15, 2026 FINRA settlement, 926,986 ONC shares were sold short, or 0.80% of shares outstanding. Days to cover: 2.6. FINRA publishes short interest twice a month, about nine business days after each settlement date.
What was BeiGene, Ltd.'s revenue?
In its latest reported fiscal year (ending December 31, 2025), BeiGene, Ltd. reported revenue of $5.34B and net income of $286.93M.
Ask your own questions about ONC
Try mrmarket.ai freeData as of August 13, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.